Clinical Trials · NCT05815680
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 48
- Start date
- Apr 2023
- Locations
- 1 site, China
- Primary endpoint
- Maximum observed metformin plasma concentration at steady state